Rspondin-Lgr Axis in Bone Regeneration

Information

  • Research Project
  • 10260493
  • ApplicationId
    10260493
  • Core Project Number
    R01DE030716
  • Full Project Number
    5R01DE030716-02
  • Serial Number
    030716
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    9/10/2020 - 3 years ago
  • Project End Date
    8/31/2025 - a year from now
  • Program Officer Name
    LUMELSKY, NADYA L
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/12/2021 - 2 years ago

Rspondin-Lgr Axis in Bone Regeneration

There is an urgent clinical need to develop new therapeutics to promote bone regeneration. A critical aspect of the bone healing process begins with the expansion of periosteal progenitors that occurs immediately after injury and then the differentiation of these progenitors to bone forming osteoblasts and chondrocytes, yet mechanisms that control skeletal progenitor/stem cell activation, expansion, and differentiation in response to injury are poorly described. Our project will study the role of the R-spondin (ligand) ? Lgr (receptor) signaling axis in regulating these progenitors and bone regeneration. R-spondins (roof plate specific spondin) are a family of four secreted matricellular proteins (Rspo1-4) that bind to Leucine-rich repeat-containing G-protein coupled receptors 4/5/6 (Lgrs). Rspo-Lgr interaction potentiate canonical Wnt pathway by preventing the turnover of Wnt Frizzled receptors, and hence determines canonical Wnt signaling levels. While canonical Wnt signaling is known to play an important role in bone regeneration, very little research has explored positive modulators of Wnt signaling. In particular, the requirement of Rspo-Lgr in the context of fracture healing has never been examined due to lack of appropriate models. Our primary goal is to define the requirement of Rspo2/3 and Lgr6 in mesenchymal progenitors in response to bone injury. We have defined three specific aims to address this goal. In Aim1, we will use single and compound Rspo2 and Rspo3 floxed mice crossed with an alphaSMACreERT2 mouse to disrupt the Rspo2/3 genes in mesenchymal progenitors at the time of fracture. Bone healing will be assessed using microCT, histology, molecular analysis, and mechanical testing. Alterations in canonical Wnt signaling and osteogenic potential of Rspo2/3 deficient progenitors will be assessed. In Aim 2, Lgr6 knockout mice will be investigated for their bone healing properties using parameters similar to Aim 1. In Aim 3, Rspo2 will be delivered to bone injury sites and the impact on BMP and Wnt signaling, progenitor activation and differentiation, and bone healing assessed. Completion of this project will identify the requirement of Rspo2/3-Lgr6 interaction in fracture healing and will provide new therapeutic directions for enhancing bone healing.

IC Name
NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
  • Activity
    R01
  • Administering IC
    DE
  • Application Type
    5
  • Direct Cost Amount
    613697
  • Indirect Cost Amount
    153126
  • Total Cost
    766823
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    121
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIAMS:375875\NIDCR:390948\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    SBSR
  • Study Section Name
    Skeletal Biology Structure and Regeneration Study Section
  • Organization Name
    UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
  • Organization Department
    ORTHOPEDICS
  • Organization DUNS
    022254226
  • Organization City
    FARMINGTON
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    060305335
  • Organization District
    UNITED STATES